Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
US10329338B2 · kind B2 · utility
0Cited by
47References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2015 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | May 12, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.